Samsung Biologics
Samsung Biologics Snaps Up Biogen’s Stake in Samsung Bioepis for $2.3 Billion, Assuming Full Control of Biosimilar Venture
2022-01-28
COVID-19: Moderna Enters Manufacturing Agreement with Samsung Biologics after Vaccine Bags Conditional Nod in South Korea
2021-05-23
Samsung Biologics Renews Manufacturing Deal to Expand Production of TG Therapeutics’ Cancer Drug
2021-04-27